What the hell happened to Breezula? 8/2/2025
Breezula (clascoterone) Phase 3 hair loss trial results are delayed, with no official updates yet. The acne version is approved, but hair loss results are still pending.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Pelage are going to do two phase 3 trials for PP405. How long will it take to complete two phase 3 trials?
Pelage plans to conduct two Phase 3 trials for PP405, a new hair loss treatment, which may take about a year to complete. Users discuss various hair loss treatments, including pyrilutamide, minoxidil, finasteride, and clascoterone, with some expressing impatience over the lengthy trial process compared to faster drug approvals like the COVID vaccine.
community Clascoterone 12 months phase 3 result out
Clascoterone is promising for hair loss, showing 24.5% improvement in satisfaction compared to placebo. Users consider it an alternative to finasteride, with concerns about absorption and side effects.
community Clascoterone study going on right now
A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.
community Breezula Phase III 12-Month Data Released by Cosmo Pharma
Clascoterone 5% topical solution is effective and safe for long-term use in treating male pattern hair loss. Cosmo Pharma aims for EU and US approval, with a potential US release in late 2027 or early 2028.
community Are these new hair loss treatments ever gonna release?
Hair loss treatments like Breezula and PP405 are delayed, with approvals taking years, while existing treatments like minoxidil and finasteride remain popular. New treatments like Clascoterone and Veradermics are in trials, but high costs and lengthy approval processes slow their release.
Related Research
6 / 6 results
research Topical Antiandrogen Therapies for Androgenetic Alopecia and Acne Vulgaris
This review discusses the potential efficacy of topical antiandrogen therapies for treating androgenetic alopecia and acne vulgaris, finding promising results but highlighting the need for more comprehensive studies.
research New drugs under investigation for the treatment of alopecias
This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.
research Industry update: the latest developments in the field of therapeutic delivery, July 2018
This industry update reports on various advancements in therapeutic delivery during July 2018, highlighting active mergers, collaborations, and potential developments across fields like gene therapy, immuno-oncology, and rare diseases treatment; however, no new clinical results are presented.
research Antiandrogens and Androgen Inhibitors
This source outlines various antiandrogen and androgen inhibitor drugs used to treat cutaneous disorders of hyperandrogenism, detailing their mechanisms, uses, dosages, and side effects, with emphasis on spironolactone, finasteride, dutasteride, and oral contraceptives.
research Androgenetic Alopecia: An Update of Treatment Options
Minoxidil is the only FDA-approved topical drug for treating male or female pattern hair loss, and other medications like finasteride and dutasteride can also increase hair growth.
research Experimental and early investigational drugs for androgenetic alopecia
This review discusses current and emerging therapeutic strategies for androgenetic alopecia, noting limited evidence but suggesting areas such as prostaglandin analogs, PRP, and progenitor cell therapies as promising future directions.